The expression level of hsa‑miR‑146a‑5p in plasma‑derived exosomes of patients with diffuse large B‑cell lymphoma
Message:
Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:
Background
The standard treatment for patients with diffuse large B‑cell lymphoma (DLBCL) had been rituximab‑based
immunochemotherapy. However, the biological and clinical heterogeneity within DLBCL seems to affect treatment outcome. Therefore,
the evaluation of miRNA levels might be useful in predicting treatment response and relapse risk. miR‑146a is a modulator of innate and acquired immunity and may play an important role in predicting treatment response. The aim of the present study was to compare the expression level of miR‑146a in plasma‑derived exosomes of responsive DLBCL patients (response to R‑CHOP (Rituximab, and Cyclophosphamide, Hydroxydaunorubicin, Oncovine and Prednisone)), refractory DLBCL patients (resistant to R‑CHOP), patients receiving R‑CHOP, and healthy donors.
Materials and Methods
After the preparation of plasma and isolation of exosomes, the presence of plasma‑derived exosome was confirmed by Zetaseizer, electron microscope, and Western blot. The patients’ medical records were collected and analyzed. The expression level of exosomal miR‑146a was evaluated in DLBCL patients and healthy donors using real‑time polymerase chain reaction (PCR). The −ΔCt values of miR‑146a were compared among responsive patients (n = 17),refractory patients (n = 16), patients receiving R‑CHOP therapy (n = 15), and healthy donors (n = 6).
Results
The presence and size of plasma‑derived exosomes were confirmed. Our findings did not show any significant difference in the expression level of exosomal miR‑146a between DLBCL patients and healthy donors (P = 0.48). As well, the clinical and histopathological parameters were not correlated with the expression level of exosomal miR‑146a or plasma miR‑146a. The expression level of plasma miR‑146 was lower than the expression level of exosomal miR‑146 (P = 0.01).
Conclusion
Exosomal miR‑146a might be useful as a promising “liquid biopsy” biomarker in predicting treatment response and relapse risk; however, we could not find significant differences due to small sample size.
Language:
English
Published:
Journal of Research in Medical Sciences, Volume:24 Issue: 2, Feb 2019
Page:
2
magiran.com/p1951049  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 990,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
دسترسی سراسری کاربران دانشگاه پیام نور!
اعضای هیئت علمی و دانشجویان دانشگاه پیام نور در سراسر کشور، در صورت ثبت نام با ایمیل دانشگاهی، تا پایان فروردین ماه 1403 به مقالات سایت دسترسی خواهند داشت!
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 50 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!